Criscitiello Carmen, Viale Giulia, Curigliano Giuseppe
Division of Experimental Therapeutics, European Institute of Oncology, Milan, Italy.
Curr Opin Oncol. 2017 Nov;29(6):428-433. doi: 10.1097/CCO.0000000000000401.
A burst of recent activity has surrounded the study of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors for the treatment of metastatic breast cancer. The success of these drugs in the metastatic setting has pushed the evaluation of these agents in early-stage disease. The use of CDK 4/6 inhibitors as neoadjuvant and adjuvant therapy is a hot topic and several studies are underway.
Ongoing studies are exploring the addition of CDK 4/6 inhibitors to endocrine therapy in early breast cancer.
Identification of the optimal treatment combinations is the goal of current research. Finding biomarkers for patients' selection will be the goal of future research.
近期围绕细胞周期蛋白依赖性激酶4/6（CDK 4/6）抑制剂治疗转移性乳腺癌的研究活动激增。这些药物在转移性疾病中的成功促使人们对其在早期疾病中的评估。将CDK 4/6抑制剂用作新辅助和辅助治疗是一个热门话题，多项研究正在进行中。
正在进行的研究正在探索在早期乳腺癌的内分泌治疗中添加CDK 4/6抑制剂。
确定最佳治疗组合是当前研究的目标。寻找用于患者选择的生物标志物将是未来研究的目标。
